The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
BACKGROUND: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia. METHODS: In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450. The two primary end points were the percent change from baseline in the LDL cholesterol level on day 510 and the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 540. RESULTS: The median age of the patients was 56 years, and 47% were men; the mean baseline level of LDL cholesterol was 153 mg per deciliter. At day 510, the percent change in the LDL cholesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001). There were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran lowered LDL-C by 47.9% in the 482 HeFH patients enrolled in ORION-9 at Day 510 [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study by Raal et al. focused on HeFH patients displayed an outlier position in the lower left quadrant of the funnel because it had both a small effect size and a wide standard error [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results were confirmed in the phase 3 ORION-9 trial which showed a − 48% LDL-C reduction of inclisiran relative to placebo among 482 patients with HeFH [138].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–820 of 820
Jaiswal, V., Deb, N., Latif, F., Shrestha, A. B., Garimella, V., Shama, N., Jitta, S. R., Naz, S., Kumar, T., Khan, S., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.06.034
Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells
Howlader, M. S. I., Das, M., Hansda, S., Siraj, M. A., & Das, H. (2026) · Biology · doi:10.3390/biology15151307
Do Chemically Modified Oligonucleotide Therapeutics Require Environmental Risk Assessment?
Hofstetter, T. B., Scheidat, I., Mansfeldt, C. B., Robinson, S. L., Sander, M., & Bürgmann, H. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.6c05885
Wu, X., & Zhang, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm48237
Ballantyne, C. M., Pirillo, A., & Catapano, A. L. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2732054
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms
Wieland, J., Jackson, P., Penrod, W., Nadauld, S., & Barrott, J. J. (2026) · Cells · doi:10.3390/cells15181647
Medication adherence: An overlooked critical determinant of pharmacological effectiveness
Burnier, M., Azizi, M., Gupta, P., Kardas, P., Schneider, M. P., & Vrijens, B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100161
Baharani, J., & Ramachandran, S. (2026) · Lipidology · doi:10.3390/lipidology3030025
Matteucci, A., Bonanni, M., Fusco, S. A. D., Aiello, A., Aquilani, S., Fedele, S., Nardi, F., & Colivicchi, F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.012
Familial Hypercholesterolemia in Latin America: Unmet Needs, Barriers, and Challenges
Rodrigo Alonso, K., & Corral, P. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.3.458
Mangla, P., Kay, E., Munson, M. J., van Leeuwen, D., Stavenhagen, K., Nahar, S., & Biscans, A. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261488803
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Li, B., Ye, C., Wang, Z., Zhang, J., Fan, Z., Huo, Y., Xianwei, W., & Lv, F. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118047
Sustained relief of chronic pain via a Nav1.7-targeting ASO-siRNA conjugate in rats
Ren, B., Yu, C., Yin, W., Yuan, Z., Chen, H., Liu, Y., Fang, B., Zhang, C., Wu, J., Liu, S., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.039
In-vivo CRISPR/Base-Editing “One-Shot” Therapies Targeting PCSK9
Nelson, B., & Khera, A. V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01470-8
Valle, C. D., Zuin, M., & Bilato, C. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70267
siRNA therapeutics: from hepatic delivery to extrahepatic targeting
Wang, N., Meng, L., Shi, J.-X., & Bartneck, M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2754564
BindingDB (2024) · UC San Diego · doi:10.7270/q21r6vzp
BindingDB (2024) · UC San Diego · doi:10.7270/q25x2f5v
Sabouret, P. F., Giamundo, D. M., Ibrahim, A., Calabrò, P., Andò, G., Pathak, M., Atar, D., & Pathak, A. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02440-x
Metadata
- Authors
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., & Kastelein, J. J. P.
- Affiliations
- University of the Witwatersrand (ZA)
- Medpace (United States) (US)
- From the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.); the Medicines Company, Zurich, Switzerland (D.K.); the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London (K.K.R.); Medpace Reference Laboratories, Cincinnati (T.T.); Deutsches Herzzentrum München, Technische Universität München, and German Center for Cardiovascular Research, Munich Heart Alliance, Munich (W.K.), and the...
- Mayo Clinic (US)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1520-1530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011005820
- Semantic Scholar
- cd7f15bcb062953bf710c34645a08f7b4818c4d9
- Cited by
- 818
- References
- 52
- Citations by year
- 2026: 88 · 2025: 126 · 2024: 142 · 2023: 154 · 2022: 140 · 2021: 111 · 2020: 56
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, heterozygous familial hypercholesterolemia, PCSK9 inhibition, siRNA, LDL cholesterol lowering, atherosclerotic cardiovascular disease prevention, hypercholesterolemia treatment, lipid-lowering therapy, PCSK9 monoclonal antibodies
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
